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An exceptionally high number of monogenic disorders lead to incurable blindness,
making them targets for the development of gene-therapy. In order to successfully
apply therapeutic vector systems in vivo, the heterogeneity of the disease phenotype
needs to be considered. This necessitates tailored approaches such as subretinal or
intravitreal injections with the aim to maximize transduction of target cell populations,
while minimizing off-target effects and surgical complications. Strategic decisions on
parameters of the application are crucial to obtain the best treatment outcomes and
patient safety. While most of the current retinal gene therapy trials utilize a subretinal
approach, a deeper understanding of the numerous factors and considerations in
choosing one delivery approach over the other for various ocular pathologies could
lead to an improved safety and treatment efficacy. In this review we survey different
vector injection techniques and parameters applied in recent retinal (pre-)clinical trials.
We explore the advantages and shortcomings of each delivery strategy in the setting
of different underlying ocular pathologies and other relevant factors. We highlight the
potential benefits for patient safety and efficacy in applying those considerations in the
decision making process.
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INTRODUCTION
A unique set of highly relevant features, conveniently combined in a single organ, have placed
the eye at the forefront of gene therapy development. As a small, compartmentalized, and paired
organ with excellent access both for intervention and high resolution functional and structural
diagnostics, the eye benefits from the vast knowledge on the genetic basis of ocular disease in
general and retinal dystrophies specifically. As multiple monogenetic causes have been identified
to lead to blinding retinal disorders, there is a rich pool of potential targets for drug development.
From a surgeon’s perspective, the eye is easily accessible using minimally invasive techniques
with its transparent media allowing a direct view of the operating field. Standard techniques and
instruments can be used to gain direct access to the inner contents of the eye. The vitreous and
retina are well defined compartments within the eye. Considered as part of the brain, the retina
consists of distinct layers in which ganglion cells and nerve fibers are situated closest to the
pupil. These are followed by more distal interneurons. The light sensing photoreceptors (PRs) are
found buried deepest in the neuroretina and interact directly with a monolayer of retinal pigment
epithelium (RPE) cells, which in turn sit on top of the Bruch’s membrane and the choroid with
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its rich capillary network. The surgeon has mainly two options to
deliver vector solution to the retina, either by injecting it into the
vitreous body which fills the core of the eye, using the so-called
intravitreal (IVT) approach, or by injecting the solution under
the sensory retina, in a potential space between the PRs and RPE,
with a subretinal (SR) injection.
In many ocular genetic disorders in clinical trial phase, a
consensus regarding the preferred injection type has already been
reached. For example, in Leber’s congenital amaurosis (RPE65
gene) in which deeply situated RPE cells are the target of gene
therapy, the SR approach is employed in all current trials (Table
1 in Supplementary Material). On the other hand, in Leber’s
hereditary optic neuropathy (LHON), a disease in which the
more superficial layer of ganglion cells is targeted, the IVT
approach has become the choice in all clinical trials. However,
in several other cases, such as in macular dystrophies and in
retinitis pigmentosa, both approaches have been suggested and
no single consensus has emerged. Some genetic diseases, like
X-linked retinoschisis and Stargardt disease, have only recently
started to gain momentum toward translation into clinical trials
and the most optimal injection method for these clinical entities
may yet to be determined. In this mini-review we seek to provide
a detailed assessment of the relevant factors and their impact on
the decision matrix in order to facilitate and guide the decision-
making process on future surgical protocols.
INTRAVITREAL INJECTION
Intravitreal (IVT) injection is a widely-used technique to
deliver therapeutic agents, the most common being drugs
inhibiting vascular endothelial growth factors, antibiotics and
glucocorticoids. IVT injections are one of the most commonly
performed ocular surgery procedures in the developed world,
second only to cataract surgery.
The procedure is generally performed under local anesthesia
with e.g., lidocaine 2%. During the procedure, the eyelids and
eyelashes are treated with disinfectant such as povidone-iodine
solution. Subsequently, a 30 Gauge needle is inserted through
the sclera at the pars plana region, 3.5–4 mm posterior to the
limbus between vertical and horizontal muscles (Figure 1). The
therapeutic agent is directly injected into the vitreous cavity with
limited reflux (Boon et al., 2008; Xing et al., 2014).
Although considered relatively safe, IVT injections bear
some degree of risk for complications. One of the major post-
injection complications is endophthalmitis, with per-injection
complication rates ranging between 0.021% (Dossarps et al.,
2015) and 0.16% (Wu et al., 2008). The majority of patients
with a history of endophthalmitis maintain reduced visual
acuity in follow-up examinations (Dossarps et al., 2015).
Other observed complications include: retinal detachment,
iritis/uveitis and transient intraocular pressure elevation (Jager
et al., 2004). The relative safety of IVT seemingly made many
practices adopt less rigorous surgical hygiene standards. For
example, 48% of the 765 surveyed retinal specialist in US
reported wearing no gloves during an IVT injection (Green-
Simms et al., 2011). Streptococcal isolates were found to be 3
times more common after IVT than after intraocular surgery
(McCannel, 2011).
When considering the IVT injection in pre-clinical settings,
key differences between the eyes of human and small animal
models need to be accounted for, namely the vitreous volume
and the lens/eye ratio. For example, the spherical lens of the rat
occupies most of its eye, leaving only a volume of 13µl that is
occupied by the vitreous and thus restricting the effective IVT
injection volume to 3–5µl (Dureau et al., 2001). The lens takes
up even more of the globe in mice, where IVT injections are
generally limited to volumes of up to 2µl (Lin et al., 2014; Rösch
et al., 2014; Du et al., 2015). Rabbits on the other hand have larger
eyes, yet their lens still occupies ∼40% of the axial length of the
eye (Trivedi et al., 2002), which allows IVT injections of up to
50–100µl (Chen et al., 2011; Gasparin et al., 2014). From the
surgical standpoint, big lenses considerably restrict the space in
which the needle can be safely maneuvered without damaging
the retina or the lens and its capsule. Tominimize the risk for lens
touch and cataract formation and/or retinal perforation, adjusted
protocols have been proposed for trans-scleral or trans-retinal
approaches (Chiu et al., 2007). In the context of gene therapy,
pre-clinical experiments on non-human primates were designed
to closely mimic the clinical administration of recombinant AAV
(rAAV). Their findings suggest that extraocular biodistribution
and shedding of rAAV vehicle after IVT injection is considerable,
especially in blood and lymphatic tissue (Seitz et al., 2016).
Consequently, a consistent humoral immune response against
rAAV can be observed c. 7 days after IVT Injection (Reichel
et al., 2016). Apart from these safety aspects, transduction
efficiency of target cells is a key variable in the context of
efficacy. When applying rAAV2 and rAAV8 (the most commonly
serotypes in clinical use) intravitreally, both serotypes show
limited transduction efficiency confined to inner retinal cells (Li
et al., 2008; Igarashi et al., 2013). One study showed two orders
of magnitude lower transduction of whole retina after IVT of
rAAV8 compared to subretinal injection in non-human primates
(Seitz et al., 2016).
SUBRETINAL INJECTION
Unlike IVT, subretinal (SR) injections constitute “proper”
ophthalmic surgery performed by vitreo-retinal surgeons. SR
maneuvers are routinely used in severe cases of submacular
hemorrhage or other complex vitreoretinal disease involving the
subretinal space. In clinical research, subretinal surgery has been
performed in macular translocation surgeries (Aisenbrey et al.,
2002), electronic (Zrenner et al., 2011), or stem-cell implants
(Schwartz et al., 2015) and gene therapy trials (Bainbridge et al.,
2008; Hauswirth et al., 2008; MacLaren et al., 2014; Banin et al.,
2015; Fischer et al., 2016a), with the aim to prevent or reverse
blindness.
The SR injection can be performed under retro-/parabulbar
anesthesia (Hauswirth et al., 2008) or under general anesthesia in
an operating theater. After disinfection, a three-port pars plana
vitrectomy is performed, mostly using standard 23 or 25G trocar
systems. After successful detachment of the posterior hyaloid
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FIGURE 1 | Diagram of routes of surgical intraocular gene therapy delivery. (A) Subretinal (SR) injection performed via the pars plana. The needle delivers the
vector solution (in light-blue) into the potential space between retinal pigment epithelium (RPE) and photoreceptors in the outer nuclear layer (ONL). (B) Intravitreal (IVT)
injection also uses the pars plana access to deliver vector solution into the vitreous cavity.
membrane and removal of the vitreous, e.g., a double-barrelled
23G needle with 41G tip is inserted through the trocar. The tip is
guided to the subretinal area and a small infusion of balanced
salt solution (BSS) is performed into the potential subretinal
space to form a bleb. Once the subretinal space has formed and
location of the bleb is within the targeted region (Figure 1), the
same retinotomy (injection channel through neuroretina) is used
to guide a second instrument with the same tip built into the
subretinal space for the injection of the therapeutic agent using
a controlled flow rate (Fischer et al., 2016b).
The described approach is the “two-step” variant of the SR
injection technique first described by Bainbridge et al. (2008) and
employed by MacLaren et al. (2014) and Fischer et al. (2016b).
Using this approach, a sub-retinal bleb of BSS solution is induced
before actual vector injection takes place. This opens the potential
subretinal space and the surgeon can ensure the correct plane has
been chosen and that the bleb is located and traveling toward the
targeted location. In contrast, the “single-step” injection used by
Maguire et al. (2008), aims to place the vector solution directly
in the subretinal space while the retina is still fully attached. The
“two-step” approach offers several advantages like the possibility
to better assess the direction of bleb spread as well as minimize
vector loss by misguided injection (e.g., accidental delivery into
vitreous, subhyloidal or suprachoroidal space).
Vitrectomy as part of the SR injection procedure is associated
with general surgical complications, including increased rate of
cataract development (Bennett et al., 2016) while the subretinal
injection per se may induce a limited degree of outer nuclear
layer (ONL) thinning (Jacobson et al., 2006). A few mild and
self-resolving subconjunctival and retinal hemorrhages were
also observed (Rakoczy et al., 2015) as well as a case of
acute endophthalmitis which resolved under antibiotic treatment
(Schwartz et al., 2015). An intraoperative macular hole has
been reported as well (Campochiaro et al., 2017). In contrast
to IVT injections, the amount of currently available data on
complications in SR injections is too limited in order to reliably
estimate the complication rates. Nonetheless, much development
effort has been concentrated to provide technical solutions that
will enable safer SR injections, such as the use of intra-operative
optical coherence tomography (OCT) imaging (Ehlers et al.,
2014) for live head-up-display visualization of the injection bleb
as well as surgical robotic solutions (Meenink et al., 2013) that
facilitate fine movements in the eye and eliminate hand-tremor
effects.
In pre-clinical settings, ab externo SR injection has been
successfully tested in mice (Fischer et al., 2013), rabbits (Peden
et al., 2011; Martorana et al., 2012), and pigs (Smet et al., 2012).
The procedure involves penetration of the conjunctiva, sclera,
choroid, and RPE at the equatorial region in order to reach the
subretinal space without disrupting the retina. A fine needle is
advanced at an angle to enter the subretinal space, while not
penetrating the retina with the tip of the needle. With the bevel
facing the photoreceptor outer segments, volume can be injected
to detach a large portion of retina in one injection. Ab externo
approaches can cause escape of any amount of the injected
volume into the suprachoroidal space, choroid or even orbita.
Because more sturdy instruments are necessary to penetrate the
sclera, the injection channel is usually larger than in a trans-
retinal approach, where extremely fine tips made by flexible
polytetrafluoroethylene are used. The larger injection channels
translate into potentially larger volume of reflux. Sparing the
retina was possible in most cases using such an approach in pigs.
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Yet 13% of the 124 performed procedures in one study resulted
in iatrogenic retinal perforations (Smet et al., 2012).
GENE DELIVERY VECTOR
The most common vector currently being used in retinal gene
therapy trials is a modified adeno-associated virus (AAV),
which offers numerous advantages, such as a high transduction
efficiency in both, dividing and non-dividing retinal cells, a
range of natural serotypes with complimentary tropism favoring
various cell populations (Ellis et al., 2013) and a good safety
profile (Trapani et al., 2014). In this text we mainly focus on AAV
as the main vector in our examples and reasoning.
ANATOMICAL LAYOUT OF TARGET
TISSUE
In each setting, multiple factors determine the best surgical
approach for vector delivery. To facilitate implementation
in decision matrix, individual factors will be highlighted
independently. The layout of the target tissue to be treated is
maybe the most obvious determinant of a preferred delivery
route. Considering the vertical lamination of the retina and
its neighboring tissues, IVT approaches would be predicted
more successful in transducing ganglion and/or bipolar cells
populating the inner retina. While diseases primarily affecting
RPE and/or photoreceptors may be most efficiently targeted by
SR injections. Recently, considerable research efforts have been
invested into developing ways to minimize the impact of this
factor on the decision outcome, such as development of mutant
AAV vector capsids capable of reaching the photoreceptors also
by IVT administration (Dalkara et al., 2013; Kay et al., 2013).
New developments in vector design could potentially provide
additional flexibility (Dalkara et al., 2013; Cronin et al., 2014).
A second anatomical consideration is the non-homogenous
cell density distribution across the surface of the retina and its
implications. The fact that cones have a sharp density peak in the
central fovea, as opposed to rods, which reach highest density at
20◦, has important functional and surgical implications (Purves
et al., 2001). The cone-mediated central visual function would
be the most relevant target for localized gene therapy if RPE
or cone photoreceptors are targeted or to prevent secondary
cone degeneration, because a therapeutic effect in the central 10◦
visual field would have the most substantial impact on the quality
of life of the patient compared to a treated peripheral island
of comparable size. When targeting a subpopulation (rods vs.
cones), the spatial density gradients become especially relevant,
as in the case of CNGA3 gene therapy for achromatopsia, where
cone photoreceptors are targeted at the area of their highest
physiological density with potentially the most significant impact
on patients’ quality of life (Banin et al., 2015).
Thirdly, the tempero-spatial pattern of disease progression
is also highly relevant. For example, in rod-cone dystrophies
progression is centripetal, with central vision being the last
to be affected by the disease. Whereas, in Stargardt’s disease,
central vision is affected early on, as disease progresses in a more
centrifugal fashion. Since gene therapy can only be successful if
the target cells are still viable, disease type, and stage need to be
considered when choosing the application approach.
These considerations usually have to be assessed as an
integrated matrix of factors in clinical scenarios. For example,
choroideremia, a progressive degenerative disease is caused by
genetic mutation or deletion ofCHM on the X-chromosome (van
denHurk et al., 1997). This leads to a degeneration of the choroid,
retina and RPE, to the extent where the intact area that can
potentially be treated in advanced stages is very limited (Barnard
et al., 2015). In such cases a SR injection is very suitable approach
to efficiently target the remaining cell groups of the outer retina
and RPE, while limiting the delivery of the vector to the treated
area and avoiding off-target exposure and minimizing systemic
spread. On the other hand, in earlier stages of choroideremia,
most of the retina is still intact and could potentially benefit from
gene-therapy. An IVT approach in this case could in principle be
advantageous, as broader areas of retinal tissue could be treated.
All six listed CHM gene therapy trials have employed the SR
approach targeting patients with advanced disease (Table 1 in
Supplementary Material).
Conversely, mutations in mitochondrial DNA at position
11,778 cause ganglion cells to degenerate, leading to LHON (Man
et al., 2002). In order to reach a great number of ganglion cells at
the surface of the inner retina, an IVT injection might be a better
option. This reasoning has likely driven the selection injection
method for LHON in current clinical trials, as all five listed trials
used this approach (Table 1 in Supplementary Material).
ANATOMICAL BARRIERS AND THEIR
INTEGRITY
The internal limiting membrane (ILM) likely acts as a barrier for
the diffusion of AAV vectors between the vitreous and the retina
(Dalkara et al., 2009). This property of the ILM can become a
major obstacle to treatment delivery or alternatively be harnessed
as a key component to achieve the therapeutic goals by choosing
the right injection method.
In IVT injection, ILM is thought to prevent the diffusion of
AAVs and transduction of target cells in the outer retina and
has been a major obstacle in the development of retinal gene
therapy for retinal dystrophies primarily affecting the RPE and/or
photoreceptors. Several methods that target ILM integrity, like
laser-based photocoagulation (Lee et al., 2013), surgical peeling
(Takahashi et al., 2017), and enzymatic lysis (Dalkara et al., 2009)
of ILM have been demonstrated to facilitate vector transduction
of the target retinal tissue via the ILM, yet not without potential
risk for complications. In the case of SR injection, the ILM likely
acts as a natural barrier that helps prevent unwanted vector
spread to the vitreous, anterior segment and systemic circulation.
To benefit from the compartmentalization of the retina
rather than try to overcome it, the surgical approach should be
optimized for the anatomical position of the target cell. With the
current vector systems, the SR delivery seems better suited for
targeting RPE or photoreceptor layers, whereas IVT injection is
optimal for targeting inner retinal neurons or Müller glia.
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MULTIPLICITY OF INFECTION
The ratio between the total number of vector particles to the
number of cells potentially transduced, also known asmultiplicity
of infection (MOI) is known to be correlated with the treatment
effect in gene therapy (MacLaren et al., 2014). Using the IVT
delivery approach, an increased amount of off-target cells will
be exposed to the vector in comparison with an SR injection
of the same total dose. This greater number of cells would
reduce the MOI in an IVT approach when comparing it to a
SR injection at a fixed dose. If this would correlate with efficacy
measures in a dose response function, IVT approach needs to
apply significantly higher numbers of vector particles to achieve
the same MOI of an SR approach. This can be achieved by using
a higher viral concentration and/or higher injection volume.
Yet, increasing the total vector dose would increase the risk
for unwanted shedding and more pronounced biodistribution,
which in turn increases the likelihood of a potentially harmful
immune response.
IMMUNE RESPONSE AND VECTOR
RE-ADMINISTRATION
Injections to different ocular compartments have been shown
to results in different humoral immune responses in mice (Li
et al., 2008) and monkeys (Seitz et al., 2016). IVT injections
triggered a humoral immune response to the AAV vehicle while
SR injections didn’t cause a humoral response nor did they
affect a repeated administration in the partner eye (Li et al.,
2008, 2009). Further studies in non-human primates (NHP)
have shown a dose dependent immunologic response also in SR
injection (Ye et al., 2016). Pre-existing anti-AAV antibodies in
NHPs strongly correlated with weak trans-gene expression when
AAV was delivered using the IVT approach (Kotterman et al.,
2015). In contrast, SR injected AAV effectively transduce retinal
cells despite the presence of neutralizing anti-AAV antibodies in
the serum and intraocular fluid (Amado et al., 2010).
SYSTEMIC VECTOR SHEDDING
The eye is considered an “immune privileged” organ, a
property that has allowed such immunologically challenging
procedures as transplants to be performed without systemic
immunosuppression in case of the cornea (Niederkorn, 2013).
The rest of the body (except the brain) does not have such a status
and therefore has a higher potential for inflammatory response
to the injected vector. Avoiding systemic spread of AAV vector
from the eye to the rest of the body is also important to minimize
the formation of neutralizing antibodies, which have been proven
to be very efficient against AAV even at low titers, leading to
complete neutralization of vector transduction in some cases
(Manno et al., 2006). AAV vector has been detected in larger
quantities and for longer time periods in all bio-fluids following
an IVT injection in comparison with SR administration (Seitz
et al., 2016).
BIOMECHANIC STABILITY OF THE RETINA
The effect of the underlying disease on the structural health
of retina has to be considered, especially when it comes to
SR injections. Fragile retinas might fail to maintain their
structural integrity when exposed to mechanical tension
induced by the injection bleb. To minimize the risk of
iatrogenic macular hole formation, injection velocity and
pressure should be tightly regulated to avoid water-jet
effect in the small diameter needle and allow gradual bleb
formation.
RETINAL ADHESIVENESS
Several underlying pathological conditions can alter the adhesive
force between outer retina and the RPE. Both, too strong
and too weak retinal adhesion could lead to complications
during a SR injection. Patients with generally elevated risk
for retinal detachment (1993; Polkinghorne and Craig, 2004)
like cases of previous detachment, extreme myopia, family
history of detachment could benefit from a tailored risk and
suitability assessment for a SR injection. Moreover, the genetic
condition in question per se should be evaluated for its effect
on the adhesiveness of the retina in the treated area (Le
Meur et al., 2006). As an example, one of the more recent
targets in gene therapy trials, the X-linked juvenile retinoschisis,
predisposes for retinal detachment, and vitreous hemorrhage
and thus might not be the optimal disease for SR injection
(George et al., 1995; Lee et al., 2009). On the other hand,
more peripheral degenerations like those seen in classical
retinitis pigmentosa (RP) cases are very unlikely to cause retinal
detachment. Strong adhesive force between retina and RPE
might lead to difficulties inducing the bleb in SR injection,
prolonging the time of intervention and increasing the risk for
complications.
CONCLUSION
The SR and IVT injection are two valid surgical delivery
approaches in gene therapy, yet substantial differences between
the two methods in numerous aspects should be taken
into consideration. SR injection is generally the preferable
approach when the outer retinal layers are targeted, especially
when treatment area is limited and localized, to harness the
immunologic benefits of vector spread restriction and in cases
where re-administration in same or partner eye is a likely
option. One obstacle of the SR approach is the learning curve
and high manual dexterity required from the operating retinal
surgeon and the potential for damage during the transretinal
manipulation, yet advancements in ocular surgery robotics
development might help overcome this hurdle in the near
future (NCT03052881). IVT injection is advantageous when
inner retinal layers and wide areas of the retina are to
be treated, in particular when retinal structural resilience is
compromised through the underlying or concomitant diseases
and where no major concerns over systemic shedding and
the off-target transduction effect are present. As mentioned
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previously, the low transduction efficiency and considerable
shedding of rAAV serotypes 2 and 8 together with the humoral
immune response that follows thereafter, have been major
hurdles that keep the IVT from becoming the preferred injection
method for ocular gene therapy. Ongoing improvements in
vector design could help overcome those limitations and
potentially make IVT both safe and efficient option for gene
therapy over the long run (Dalkara et al., 2013; Kay et al.,
2013).
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